Rare Daily Staff
Rare disease patient-data platform developer Raremark said it raised $3.9 million (£3 million) in a venture round to advance it patient engagement and data-analysis technology.
AlbionVC and Ananda Ventures led the round, with participation from Oltre Venture and from existing major investor the Cass Entrepreneurship Fund.
Raremark’s platform is designed to help biopharmaceutical companies to identify, engage, and learn from patients to accelerate the development of new treatments. It provides companies access to anonymized and aggregated patient data, helping to reduce the time and cost of clinical development.
“Healthcare is becoming increasingly personalized, and precision medicine is enabling the right treatments to be delivered to the right patients,” said Julie Walters, CEO and founder of Raremark. “However, accessing credible and structured, real-world patient data remains one of the most acute challenges facing drug development in rare disease.”
October 22, 2018
Photo: Julie Walters, CEO and founder of Raremark